Literature DB >> 14668186

N-acetylcysteine as an additive to crystalloid cardioplegia increased oxidative stress capacity in CABG patients.

Antti E Vento1, Arto Nemlander, Juha Aittomäki, Jarmo Salo, Janne Karhunen, O Juhani Rämö.   

Abstract

OBJECTIVE: This prospective, randomized study was designed to assess the effects of N-acetylcysteine (NAC) in coronary artery bypass graft (CABG) patients.
DESIGN: Thirty-five consenting CABG patients with normal myocardial function were randomly divided into control (C) patients (N = 20) who received crystalloid (Plegisol) cardioplegia, and NAC patients receiving NAC in a 0.04 mol/l solution (N = 15) in Plegisol. Simultaneous coronary sinus and aortic blood samples, and myocardial biopsies were taken 1, 5 and 10 min after declamping. Hemodynamics was measured invasively for 24 h.
RESULTS: There were no adverse effects observed. The myocardial glutathione content was significantly better preserved (p = 0.0001) and myeloperoxidase activity was over two times lower in the NAC group than in the C group (p = 0.03). The trap capacity gradient between the aorta and the coronary sinus increased significantly during the first minute of reperfusion in the treatment group (p = 0.001) when compared with the C group. In the first minute after reperfusion there were more leukocytes sequestered in the coronary circulation (p = 0.04) in the C group. The invasive hemodynamic data did not differ significantly between the groups. The incidence of arrhythmias was equal.
CONCLUSION: NAC increased tissue capacity against oxidative stress and decreased inflammatory response in CABG patients with normal ejection fraction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14668186     DOI: 10.1080/14017430310015406

Source DB:  PubMed          Journal:  Scand Cardiovasc J        ISSN: 1401-7431            Impact factor:   1.589


  6 in total

1.  Adding ROS quenchers to cold K+ cardioplegia reduces superoxide emission during 2-hour global cold cardiac ischemia.

Authors:  Mohammed Aldakkak; David F Stowe; James S Heisner; Matthias L Riess; Amadou K S Camara
Journal:  J Cardiovasc Pharmacol Ther       Date:  2011-01-31       Impact factor: 2.457

2.  Efficacy of N-acetylcysteine in Preventing Acute Kidney Injury and Major Adverse Cardiac Events After Cardiac Surgery: A Meta-Analysis and Trial Sequential Analysis.

Authors:  Jingtao Zhao; Maowei Li; Chen Tan
Journal:  Front Med (Lausanne)       Date:  2022-06-22

3.  Oral N-acetylcysteine as an adjunct to standard medical therapy improved heart function in cases with stable class II and III systolic heart failure.

Authors:  Amirhossein Yazdi; Nakisa Khansari; Maryam Mehrpooya; Younes Mohammadi; Shiva Zareie
Journal:  Ir J Med Sci       Date:  2021-11-02       Impact factor: 2.089

Review 4.  Cardiopulmonary bypass and oxidative stress.

Authors:  Mustafa Zakkar; Gustavo Guida; M-Saadeh Suleiman; Gianni D Angelini
Journal:  Oxid Med Cell Longev       Date:  2015-02-04       Impact factor: 6.543

5.  N-acetylcysteine use among patients undergoing cardiac surgery: A systematic review and meta-analysis of randomized trials.

Authors:  José Eduardo G Pereira; Regina El Dib; Leandro G Braz; Janaina Escudero; Jason Hayes; Bradley C Johnston
Journal:  PLoS One       Date:  2019-05-09       Impact factor: 3.240

Review 6.  Oxidative Stress after Surgery on the Immature Heart.

Authors:  Daniel Fudulu; Gianni Angelini
Journal:  Oxid Med Cell Longev       Date:  2016-03-31       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.